Innovent Biologics Announces U.S. FDA IND Approval for the First Global MRCT Phase 3 Study (MarsLight-11) of IBI363 (PD-1/IL-2α-bias) in Squamous Non-Small Cell Lung Cancer“SAN FRANCISCO and SUZHOU, China, Aug. 24, 2025 /PRNewswire/ — Innovent Biologics, Inc....
Neoadjuvant Immunotherapy Shows Promise in Limited-Stage SCLC“Key Takeaways: Neoadjuvant chemoimmunotherapy in LS-SCLC shows high pCR and MPR rates, indicating promising efficacy before surgery. The meta-analysis found a 95% R0 surgical resection rate, with no...
3,000 steps a day at a faster pace may lower cardiovascular risks by 17%“Increasing daily step counts and walking faster may reduce risk of cardiovascular events in people with hypertension, a recent study has found. Walking more than 3,000 steps each day reduced risk...
High risk of hepatic complications in kidney transplantation with chronic hepatitis C virus infection “Data on liver issues including liver cirrhosis, hepatocellular carcinoma, and hepatic failure in renal transplant patients with HCV infection are scarce. In the...
Lung Cancer in Special Populations“Lung cancer is the leading cause of cancer deaths worldwide, claiming more lives than other age-related and screen-detectable cancers. Cigarette smoking remains the most important risk factor. However, despite common perceptions,...
More News and Updates